Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival

Table 5 Association of tumoral BRD4 expression with clinicopathologic parameters

Characteristic	BRD4/low	%	BRD4/high	%	P-value**
	(n = 143)		(n = 469)
	Number		Number
Number of Recurrences	16	11.2	68	14.5
Menopausal status
Pre	30	21.0	172	36.7	0.0018
Peri	6	4.2	22	4.7
Post	106	74.1	274	58.4
ND‡	1	0.7	1	0.2
Lymphatic Invasion
Yes	19	13.3	56	12.0	0.6592
No	123	86.0	411	87.6
ND‡	1	0.7	2	0.4
Tumor Size
< =0.5 cm	3	2.1	6	1.3	0.0049
> 0.5 to 1 cm	26	18.2	37	7.9
> 1 to 2 cm	64	44.8	213	45.4
> 2 to 5 cm	45	31.5	193	41.2
> 5 cm	4	2.8	19	4.1
ND‡	1	0.7	1	0.2
Estrogen receptor
Positive	87	60.8	302	64.4	0.1249
Negative/Equivocal	28	19.6	108	23.0
ND‡	28	19.6	59	12.6
Progesterone receptor
Positive	80	55.9	267	56.9	0.0935
Negative/Equivocal	35	24.5	143	30.5
ND‡	28	19.6	59	12.6
Histological grade
1^a	49	34.3	142	30.3	0.1497
2	53	37.1	157	33.5
3	25	17.5	127	27.1
ND‡	16	11.2	43	9.2
Adjuvant treatment
Hormonal	70	49.0	193	41.2	0.2223
Chemotherapy	16	11.2	82	17.5
Both	4	2.8	13	2.8
None	52	36.4	180	38.4
ND‡	1	0.7	1	0.2
Age (years)
Mean	58.25		55.14
SD	10.13		11.86
Minimum	33.51		25.49
Maximum	73.82		75.82

ISSN: 1471-2407